Phaseline

Companies › Carnot Laboratories

Carnot Laboratories: clinical trials, targets and expected readouts

1 active drug program in 6 registered trials: 3 Phase 4, 2 Phase 2, 1 Phase 3; Neurology, Cardiovascular, Gastroenterology, Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tegoprazan
Potassium-transporting ATPase blocker
ATP4A, ATP4BPhase 4Gastroesophageal Reflux Disease; Helicobacter Pylori Infection Chronic Gastrit; Coronary Artery Disease; Ischemic Stroke …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06523764TegoprazanPhase 4Helicobacter Pylori Infection Chronic GastritInfectious diseaseAug 2025
NCT07242456TegoprazanPhase 2Helicobacter Pylori InfectionInfectious diseaseNov 2025
NCT06991348TegoprazanPhase 4Gastroesophageal Reflux DiseaseGastroenterologyNov 2025
NCT07708545TegoprazanPhase 2Peptic Ulcer BleedingGastroenterologyDec 2026
NCT07687706TegoprazanPhase 3Ischemic StrokeNeurologyJun 2027
NCT04416581TegoprazanPhase 4Coronary Artery DiseaseCardiovascularDec 2027

Targets

ATP4A (1) ATP4B (1)

Companies with the same targets

Phathom Pharmaceuticals Il-Yang Pharm. AstraZeneca Cinclus Pharma Holding

Companies built like this

Phathom Pharmaceuticals Cinclus Pharma Holding Khondrion Shin Poong Pharmaceutical CSPC Mingfule Pharmaceutical (Guangzhou)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.